LOGIN  |  REGISTER
Amneal Pharmaceuticals

Latest Collaboration News

Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

August 13
Last Trade: 21.95 1.65 8.13

Safety review leading to dose escalation and achievement of first predetermined enrollment target in Phase 1/2 study of SRP-1003 for DM1 triggers $100 million milestone payment Sarepta sells at least $174 million of Arrowhead common stock for cash proceeds, Arrowhead will redeem $50 million of stock from Sarepta to prefund half of $100 million milestone payment due to Arrowhead CAMBRIDGE, Mass. / Aug 13, 2025 / Business Wire / Sarepta...Read more


Humana and DrFirst Partner on Innovation to Fill Gaps in Care, Improve Outcomes for Patients with Diabetes and Other Chronic Conditions

August 13
Last Trade: 286.39 5.05 1.79

Program Designed to Increase Use of Recommended Medication Therapy by Connecting with Providers in Workflow LOUISVILLE, Ky. and ARLINGTON, Va., Aug. 13, 2025 /PRNewswire/ -- Humana Inc. (NYSE: HUM), one of the nation's leading health and well-being companies, and health technology pioneer DrFirst today announced the launch of a program designed to close gaps in care for patients with chronic health conditions like diabetes and...Read more


BioMark Diagnostics Establishes African Market Presence Through Strategic Tunisia Healthcare Partnership

August 12
Last Trade: 0.36 0.00 0.00

Proof-of-Concept Trial Opens Door to 90+ Million Population Across North Africa and Francophone Markets Vancouver, British Columbia--(Newsfile Corp. - August 12, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy tests for early cancer detection, announced today a strategic Expression of Interest (EOI) agreement with SAMA CONSULTING SARL ("SAMA...Read more


Rakovina Therapeutics and NanoPalm Sign Letter of Intent to Form Joint Venture Leveraging AI-Discovered Oncology Therapies and Novel Lipid Nanoparticle Delivery Technologies

August 12
Last Trade: 0.55 -0.02 -3.51

KT-3283, a dual PARP-HDAC inhibitor, to serve as first development program in NanoPalm’s strategic expansion into the oncology field VANCOUVER, British Columbia and RIYADH, Saudi Arabia, Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through artificial intelligence (AI)-powered drug discovery and NanoPalm Ltd.,...Read more


Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target

August 7
Last Trade: 2.93 -0.07 -2.33

Almirall selects second target in AI Drug Creation collaboration Expanded collaboration builds on Absci’s successful de novo molecule design for difficult‑to‑drug targets in the first stage of the collaboration with Almirall BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a...Read more


Actuate Therapeutics To Collaborate with Incyte and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer

August 6
Last Trade: 8.12 -0.10 -1.22

Clinical Trial Study to be Conducted at UPMC Hillman Cancer to Evaluate Novel Combination as Frontline Therapy CHICAGO and FORT WORTH, Texas, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3...Read more


Standard BioTools and Precision Health Research, Singapore (PRECISE-SG100K) Launch Proteomics Collaboration, Selecting SomaScan to Power Large-Scale Population Health Study

August 6
Last Trade: 1.23 0.01 0.82

PRECISE-SG100K will run 100,000 samples as part of an effort to transform precision health and medicine Reinforces SomaScan’s strategic position in the high-impact biobank segment and its increasing role in leading global health initiatives SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that the Precision Health Research, Singapore (PRECISE-SG100K) selected the...Read more


SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

August 5
Last Trade: 3.47 0.18 5.47

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collaboration will leverage SOPHiA GENETICS's multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for...Read more


American Cancer Society and Guardant Health Partner to Expand Cancer Screening Access and Advance Health Equity

August 4
Last Trade: 58.88 -1.48 -2.45

Together, American Cancer Society and Guardant Health aim to remove barriers and increase cancer screening rates in communities that have historically limited access to preventive cancer care. SAN FRANCISCO / Aug 04, 2025 / Business Wire / The American Cancer Society (ACS) today announced a new partnership with Guardant Health (Nasdaq: GH), a leading precision oncology company focused on improving access to cancer screening and...Read more


Medicus Pharma Announces a Memorandum of Understanding (MOU) with Helix Nanotechnologies to Develop Thermostable Infectious Disease Vaccines

August 4
Last Trade: 5.69 0.00 0.00

The MOU intends to combine proprietary mRNA vaccine platform of HelixNano with proprietary Microneedle array (MNA) delivery platform of Medicus. Philadelphia, Pennsylvania--(Newsfile Corp. - August 4, 2025) - Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus") and Helix Nanotechnologies Inc. ("HelixNano"), a Boston-based biotech company focused on developing an advanced mRNA platform to create vaccines and therapies to augment the immune...Read more


Arrowhead Pharmaceuticals Subsidiary Visirna Sells Rights to Hypertriglyceridemia Candidate Plozasiran in Greater China to Sanofi

August 1
Last Trade: 20.51 1.73 9.21

Sanofi to pay $130 million upfront and up to $265 million in potential regulatory milestones to Visirna Therapeutics, a majority-owned subsidiary of Arrowhead, which was previously granted rights to investigational plozasiran in Greater China Sanofi will receive an exclusive license to develop and commercialize investigational plozasiran in Greater China from Visirna Therapeutics, offering potential treatment to people living with...Read more


Azenta Partners with Frenova, a Division of Fresenius Medical Care, and Nephronomics to Advance Genomic Research in Nephrology

July 31
Last Trade: 30.39 -0.20 -0.65

BURLINGTON, Mass., July 31, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason® genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to enhance...Read more


Fresenius Medical Care's Third-Party Clinical Research Organization Frenova Announces Strategic Collaboration Advancing Genomics-Driven, Precision Kidney Disease Care

July 31
Last Trade: 25.08 0.21 0.84

Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life Sciences Provides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registry Paves way for advances in precision kidney disease care, novel therapies, and diagnostics BAD HOMBURG, Germany, July 31, 2025 /PRNewswire/ --...Read more


Repligen Announces Strategic Partnership with Novasign to Further Advance Bioprocessing Digitalization

July 31
Last Trade: 124.35 -2.30 -1.82

WALTHAM, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced Novasign and Repligen have entered into a strategic partnership to develop and integrate Novasign’s machine learning and modeling workflow into Repligen filtration systems. As part of the partnership, Repligen will invest in Novasign to help scale and expand...Read more


Exact Sciences and Humana Expand Colorectal Cancer Screening Partnership with Cologuard Plus™ Test

July 31
Last Trade: 45.60 0.61 1.36

Cologuard Plus™ Available In-Network August 2025 MADISON, Wis. / Jul 31, 2025 / Business Wire / Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced an expanded partnership with Humana Inc. to enhance access to colorectal cancer (CRC) screening. Through the partnership, the Cologuard Plus™ test will be available as an in-network service for eligible Humana Medicare Advantage...Read more


Xenetic Biosciences Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma

July 30
Last Trade: 2.86 -0.07 -2.39

Investigator initiated study with collaboration partner, PeriNess, to be conducted at the Tel-Aviv Sourasky Medical Center FRAMINGHAM, MA / ACCESS Newswire / July 30, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its collaboration partner, PeriNess Ltd....Read more


MiMedx Announces Strategic Collaboration with Vaporox

July 30
Last Trade: 7.11 -0.04 -0.56

Relationship Establishes Co-Promotion and Co-Marketing of MIMEDX’s Leading Placental Allograft Portfolio and Vaporox’s Vaporous Hyperoxia Treatment Device MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings. As part of the...Read more


NetraMark Announces Partnership with Pentara to Detect Anomalous Site and Participant Behavior and Safeguard Clinical Trial Integrity

July 30
Last Trade: 1.58 0.11 7.48

TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and Pentara Corporation (“Pentara”), a company offering clinical data analysis services to the pharmaceutical and biotechnology industries today announced they have entered into an agreement. NetraMark, in collaboration...Read more


Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments

July 30
Last Trade: 18.54 0.12 0.65

Kissei obtains an exclusive license to develop and commercialize veligrotug and VRDN-003 in Japan  Viridian to receive an upfront payment of $70 million  Additionally, Viridian is eligible to receive up to an additional $315 million in development, regulatory, and commercial milestone payments as well as tiered royalties on net sales in Japan in the 20s to mid-30s percent  Collaboration combines Viridian’s potential...Read more


Rakovina Therapeutics Highlights Long-Standing Collaboration with the University of British Columbia and the Vancouver Prostate Centre

July 30
Last Trade: 0.55 -0.02 -3.51

VANCOUVER, British Columbia, July 30, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing cancer therapies through AI-powered drug discovery, is pleased to highlight its long-standing collaboration with the University of British Columbia (UBC) and its affiliated Vancouver Prostate Centre (VPC), one of Canada’s leading cancer research...Read more


Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site

July 30
Last Trade: 3.76 -0.06 -1.57

Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just - Evotec Biologics' advanced continuous manufacturing technology The deal terms include the purchase price of the site for around US$ 300 m in cash, and in...Read more


Simulations Plus and the Institute of Medical Biology of the Polish Academy of Sciences Partnership Announces Results in Validation of ADMET Predictor® Models with Enhanced AI Drug Design

July 29
Last Trade: 14.24 0.04 0.28

Researchers found 70% of compounds designed in ADMET Predictor demonstrated significant activity during in vitro testing RESEARCH TRIANGLE PARK, N.C. / Jul 29, 2025 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that...Read more


Rapid Dose Therapeutics and Eco Canadian Organic Initiate Health Canada Funded SUAP Harm Reduction Pilot Project on First Nations Using QuickStrip(TM) to Combat Opiate Addiction Crisis

July 29
Last Trade: 0.18 0.00 0.00

Burlington, Ontario--(Newsfile Corp. - July 29, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company"), a Canadian biotechnology company, is proud to announce the launch of a new significant harm reduction initiative aimed at addressing the devastating opioid crisis gripping Canada's First Nations communities. In collaboration with RDT and Eco Canadian Organic Inc. (ECO), a leading expert in opioid...Read more


Avalon GloboCare Enters into Distribution Agreement with Saga Health for KetoAir Targeting First Responders

July 28
Last Trade: 2.26 0.07 3.20

FREEHOLD, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that its subsidiary, Q&A Distribution, LLC, has entered into a wholesale distribution agreement with Saga Health Corporation (“Saga Health”) for its use of the KetoAir™ breathalyzer device in its first responder-targeted Holistic Health Reset...Read more


NetraMark Signs Contract with AlgoTx to Enhance Clinical Trial Design for ATX01

July 28
Last Trade: 1.58 0.11 7.48

TORONTO, July 28, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and AlgoTherapeutix SAS ("AlgoTx"), a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN) today announced they have entered into an agreement. Under...Read more


Talkspace Announces New In-Network Partnership with Blue Cross of Idaho

July 28
Last Trade: 2.56 0.03 1.19

Blue Cross of Idaho Members Across All Lines of Business Now Have Access to High-Quality Tele-Mental Healthcare NEW YORK / Jul 28, 2025 / Business Wire / Talkspace, a leading online behavioral health company, today announced a new in-network partnership with Blue Cross of Idaho to increase behavioral health access across Idaho. As of July 1, 2025, all Blue Cross Idaho members now have access to Talkspace’s comprehensive virtual...Read more


Xenetic Biosciences Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform

July 23
Last Trade: 2.86 -0.07 -2.39

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate DNase-I data demonstrated to date FRAMINGHAM, MA / ACCESS Newswire / July 23, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing hard to treat oncology indications, today announced it has...Read more


AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease

July 23
Last Trade: 1.07 0.01 0.94

DNDi to share extensive clinical trial network and expertise to rapidly advance the clinical development of AN2’s oral drug candidate AN2-502998, which has curative potential for chronic Chagas disease Startup activities underway for Phase 1 first in human study for oral AN2-502998; Phase 2 study initiation planned for 2026 Chagas disease is a life-threatening disease that affects 6 to 7 million people worldwide, including an estimated...Read more


Hoth Therapeutics Signs VA Research Deal to Advance GDNF as Breakthrough Therapy for Obesity and Fatty Liver - Side-by-Side Study vs. Semaglutide Begins

July 22
Last Trade: 1.28 -0.01 -0.78

NEW YORK, July 22, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharma innovator, today announced a CRADA (Cooperative Research and Development Agreement) with the U.S. Department of Veterans Affairs and Foundation for Atlanta Veterans Education and Research (FAVER) to evaluate GDNF (glial cell-derived neurotrophic factor) as a novel metabolic therapy targeting obesity and hepatic steatosis (fatty liver...Read more


Pacira BioSciences Announces Strategic Collaboration to Significantly Expand ZILRETTA Promotional Efforts

July 22
Last Trade: 24.78 -0.21 -0.84

Partnership expected to advance 5x30 strategy by increasing ZILRETTA sales calls and extensively expanding patient access BRISBANE, CA, July 22, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of patients, today announced a strategic collaboration1 with Johnson & Johnson MedTech to significantly expand the market...Read more


Sutro Biopharma Announces Research Collaboration with the FDA to Advance Regulatory Standards for Antibody Drug Conjugates

July 22
Last Trade: 0.88 0.10 12.55

SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it has entered into a collaboration with the U.S. Food and Drug Administration (FDA) to develop reference materials to improve regulatory standards and enhance analytical methods for ADC drug...Read more


NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan

July 17
Last Trade: 0.14 0.00 0.00

In connection with HekaBio’s recently announced strategic investment in NKGen, the partnership will expedite the regulatory, manufacturing, and commercial development of NKGen’s autologous NK cell therapy, troculeucel, in Japan. Under Japan’s Regenerative Medicine guidelines, cell therapies enjoy a regulatory environment with multiple paths for expedited commercialization. Troculeucel is well positioned to be the first-in-class...Read more


10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

July 17
Last Trade: 13.36 0.12 0.91

Ambitious study will profile thousands of tumor samples to uncover novel biomarkers and therapeutic targets for cancer and inflammatory diseases PLEASANTON, Calif. and SINGAPORE, July 17, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, and the A*STAR Genome Institute of Singapore (A*STAR GIS), today announced a research collaboration for the Target Inference from Spatialomics...Read more


Ajax Therapeutics and Schrödinger Expand Research Collaboration to Include Additional JAK Target

July 17
Last Trade: 19.38 -0.07 -0.36

NEW YORK & CAMBRIDGE, Mass. / Jul 17, 2025 / Business Wire / Ajax Therapeutics, Inc. and Schrödinger, Inc. (Nasdaq: SDGR) today announced an expansion of their exclusive research collaboration to include a new Janus kinase (JAK) target. The partnership was established in 2019 with a goal of leveraging Schrödinger’s advanced computational platform and Ajax’s structural biology insights to develop a pipeline of novel molecules, with a...Read more


60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

July 17
Last Trade: 1.32 0.01 0.76

Study will evaluate activity of tafenoquine against vector-borne pathogens, Borrelia (Lyme disease) and Bartonella in cell culture Borrelia and Bartonella, together with Babesia, represent the "3Bs," pathogens most often present in individuals with tick-borne illness such as Lyme disease WASHINGTON, July 17, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a...Read more


Oragenics Announces U.S.-Based Drug Manufacturing Agreement to Support ONP-002 Clinical Development

July 16
Last Trade: 1.13 -0.06 -4.96

SARASOTA, Fla., July 16, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company developing intranasal therapeutics for brain-related conditions, today announced it has entered into a manufacturing agreement with Sterling Pharma Solutions, an industry leading CDMO with multiple US-based development and manufacturing facilities. Oragenics has partnered with Sterling Pharma Solutions for the GMP production of...Read more


Thermo Fisher Scientific and Sanofi Expand Strategic Partnership to Enable Additional U.S. Drug Product Manufacturing

July 16
Last Trade: 489.01 3.97 0.82

Thermo Fisher to Acquire Sanofi’s Steriles Manufacturing Site in Ridgefield, New Jersey to Produce Critical Medicines for Sanofi Enables Additional U.S. Manufacturing Capacity to Serve Increased Demand for Pharma/Biotech Customers WALTHAM, Mass. / Jul 16, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to...Read more


Bio-Techne and Spear Bio Announce Strategic Partnership to Advance Therapeutic Development with Ultrasensitive Biomarker Detection

July 15
Last Trade: 53.60 -0.14 -0.26

MINNEAPOLIS, July 15, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a strategic partnership to distribute Spear Bio's next-generation ultrasensitive immunoassays, enabling the detection of low-abundance biomarkers in neurology. Under the agreement, Bio-Techne will distribute Spear Bio's ultrasensitive immunoassays for challenging low-abundance biomarkers, including key Alzheimer's disease biomarkers such as...Read more


Progyny Partners with ŌURA to Empower Women and Their Care Teams with Wearable Tech Data, Further Supporting Outcomes from Preconception to Menopause

July 10
Last Trade: 23.40 0.85 3.77

NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, today announced a new partnership with ŌURA, maker of the world’s leading smart ring, further empowering women to better understand and take action on their health through comprehensive data and personalized insights. By incorporating wearable data and insights from ŌURA into the care team...Read more


Personalis Expands Tempus Strategic Collaboration to Bring Ultra-Sensitive Cancer Recurrence Testing to Colorectal Cancer Patients

July 9
Last Trade: 4.60 -0.06 -1.29

Collaboration extension through 2029 accelerates access to MRD technology across four major cancer types FREMONT, Calif. / Jul 09, 2025 / Business Wire / Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and...Read more


Sernova Biotherapeutics Announces Collaboration with Eledon Pharmaceuticals to Advance a Potential Functional Cure for Type 1 Diabetes

July 9
Last Trade: 0.20 0.005 2.56

Tegoprubart to be Used as Immunosuppressive Agent in Cohort C of Sernova’s Phase 1/2 Cell Pouch Bio-hybrid Organ Clinical Trial in Patients with Type 1 Diabetes LONDON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics (“Sernova”) (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH) today announced a Collaborative Research Agreement with Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) to evaluate Eledon’s...Read more


Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law

July 9
Last Trade: 3.48 0.02 0.58

Fountain Life operates four flagship longevity centers, including two in Florida, where a new state law effective July 1, 2025, authorizes licensed physicians to administer stem cell therapies to members with conditions in orthopedics, wound care, and pain management. FLORHAM PARK, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing...Read more


Gilead Sciences Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

July 9
Last Trade: 118.37 -0.65 -0.55

Strategic Partnership Agreement is Part of Gilead’s Commitment to Provide Lenacapavir at No Profit in High-Incidence, Resource-Limited Countries Until Licensed Generics Can Fully Meet Demand  FOSTER CITY, Calif. / Jul 09, 2025 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply...Read more


Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic’s AI Discovery Tools to Pursue New Drug Candidates

July 9
Last Trade: 36.32 0.30 0.83

Custom-built model will be trained using Revolution Medicines’ proprietary data to discover novel drug candidates Iambic to receive up to $25 million through a combination of upfront and expected near-term performance-based milestone payments for services related to Revolution Medicines’ access to Iambic’s industry-leading NeuralPLexer model for protein structure prediction REDWOOD CITY, Calif. and SAN DIEGO, July 09, 2025 (GLOBE...Read more


Certara Announces Expansion of Clinical Technology Collaboration with Merck

July 8
Last Trade: 11.02 0.05 0.46

Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and quality RADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara Pinnacle 21 software platform to...Read more


Adagene and ConjugateBio Partner to Develop Novel Antibody Drug Conjugate

July 8
Last Trade: 1.69 -0.32 -15.92

Adagene to provide proprietary antibody to ConjugateBio for development as novel bispecific ADCs SAN DIEGO and SUZHOU, China and PRINCETON, N.J., July 08, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced a partnership with ConjugateBio Inc. (ConjugateBio) to provide a proprietary antibody for use in partner...Read more


Fresenius Medical Care Collaborates with Coordination of National Institutes of Health and Specialty Hospital to Extend Access to Innovative Dialysis Therapy in Mexico

July 3
Last Trade: 25.08 0.21 0.84

High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treated Fresenius Medical Care is committed to expanding HighVolumeHDF therapy to all markets where it is not already present, including the United States BAD HOMBURG, Germany, July 3, 2025 /PRNewswire/ -- Fresenius Medical Care (FME), the...Read more


Invivyd and Leading Researchers Form SPEAR (Spike Protein Elimination and Recovery) Study Group to Assess the Effects of Monoclonal Antibody Therapy for Long COVID and COVID-19 Post-Vaccination Syndrome

July 2
Last Trade: 0.71 -0.09 -11.55

SPEAR Study Group initiated following multiple, independent reports of substantial clinical benefit associated with PEMGARDA® (pemivibart) therapy among people with Long COVID SPEAR Study Group collaborators Drs. Michael Peluso, Amy Proal, and David Putrino are key thought leaders in the clinical and translational biology of Long COVID and Post-Vaccination Syndrome Initial SPEAR clinical efforts to be aimed at rigorous, controlled...Read more


Nano-X Imaging Announces Clinical and Educational Collaboration with Keiser University Featuring the Nanox.ARC

July 1
Last Trade: 4.42 -0.08 -1.78

Nanox.ARC delivers advanced 3D imaging with proprietary cold cathode technology Clinical studies show superior diagnostic performance to X-ray with reduced radiation exposure compared to CT PETACH TIKVA, Israel, July 01, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company", Nasdaq: NNOX), an innovative medical imaging technology company, today announced a clinical and educational collaboration with Keiser...Read more


Adaptive Biotechnologies and Flatiron Health Announce Integration of clonoSEQ® MRD Testing into OncoEMR®

July 1
Last Trade: 13.04 0.12 0.93

SEATTLE, July 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and Flatiron Health, a leading healthtech company dedicated to expanding the possibilities of point-of-care solutions in oncology, today announced the integration of Adaptive’s...Read more


Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts

July 1
Last Trade: 5.96 -0.19 -3.09

Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule  Verrica to receive a $10 million milestone payment from Torii in cash upon the approval of YCANTH® (TO-208 in Japan) for molluscum contagiosum in Japan; approval decision expected by the end of 2025  Torii to fund the first $40 million of out-of-pocket costs for the global study, representing...Read more


Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors

June 30
Last Trade: 36.32 0.30 0.83

REDWOOD CITY, Calif. and MIAMI, June 30, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers and Summit Therapeutics, Inc. (Nasdaq: SMMT), a biopharmaceutical oncology company focused on patient-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious...Read more


RetinalGenix Technologies Contracts with LabCorp to Support DNA/GPS Platform for Advanced Genetic and Retinal Health Screening

June 27
Last Trade: 3.54 0.00 0.00

Cost-Efficient Methodology Aims To Reduce Reliance On Expensive Diagnostic Procedures Such As MRI, CT Scans, PET Scans, and Echocardiograms APOLLO BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. OTCQB:RTGN (“RetinalGenix” or the “Company”), a pioneering developmental-stage company focused on ophthalmic screening, monitoring, pharmacogenetic mapping, and repurposed drug development for early...Read more


Ainos and ASE Technology Broaden Strategic Partnership to Target Deploy Up to 15,000 AI Nose Across Key Sites

June 27
Last Trade: 3.46 -0.36 -9.42

Relationship Broadens Scope to Key ASE and SPIL Facilities with Multi-Phase Deployment Milestone Positions ASEH and Ainos as First-Mover in AI-Powered Scent Intelligence for the Semiconductor Industry SAN DIEGO, CALIFORNIA / ACCESS Newswire / June 27, 2025 / Ainos, Inc. (NASDAQ:AIMD) (NASDAQ:AIMDW) ("Ainos" or the "Company") , a leader in AI-driven scent digitization, today announced the expansion of its strategic relationship with...Read more


Achieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two Decades

June 26
Last Trade: 2.55 0.00 0.00

Omnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more effective path to address a critical public health need SEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company...Read more


Novo Nordisk continues efforts to support patient access to authentic, FDA approved Wegovy® and prioritize patient safety

June 26
Last Trade: 52.36 1.41 2.77

Novo Nordisk announces collaboration with WeightWatchers to offer patients living with obesity access to FDA-approved Wegovy® through NovoCare® Pharmacy Ro and LifeMD collaborations continue based on their commitment to providing safe and effective medical treatment for patients living with chronic diseases; dialogue with other companies ongoing A new $299 savings offer, available from July 1 – July 31, 2025, is designed to help new...Read more


DarioHealth and GreenKey Health Announce Strategic Commercial Agreement to Transform Chronic Condition Management and Sleep Health for Payers Nationwide

June 26
Last Trade: 0.45 0.01 2.80

Dario and GreenKey Join Forces to Target $150 Billion Sleep Apnea Market, Addressing 29 Million Americans with Unmet Needs Through Integrated Chronic Care Solution NEW YORK and SAN FRANCISCO, June 26, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ('Dario' or the 'Company'), a leader in the global digital health market, today announced a strategic commercial agreement with GreenKey Health ('GreenKey'), an innovator in...Read more


Avalon GloboCare and Qi Diagnostics Enter into Definitive Agreement to Co-Develop Real-Time Cannabis Breathalyzer for Detecting Potential Impaired Driving

June 26
Last Trade: 2.26 0.07 3.20

FREEHOLD, N.J., June 26, 2025 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of precision diagnostic consumer products, today announced that it entered into a definitive agreement with Qi Diagnostics Limited (“Qi Diagnostics”), a nanosensor-based diagnostic technologies company, to co-develop a VOC (volatile organic compound) nanosensor-based point-of-care cannabis breathalyzer. Through...Read more


Veeva Systems and AWS Expand 10-Year Relationship

June 25
Last Trade: 280.61 5.63 2.05

AWS compute, database, and global infrastructure support Veeva’s industry cloud for life sciences PLEASANTON, Calif. & SEATTLE / Jun 25, 2025 / Business Wire / Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN), and Veeva Systems (NYSE: VEEV), a leading provider of software, data, and business consulting for the life sciences industry, today announced an expansion of their long-standing collaboration. Veeva...Read more


Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

June 25
Last Trade: 0.71 0.02 2.59

Technology Co-Developed by the U.S. Department of Veterans Affairs and Emory University NEW YORK, June 25, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics,...Read more


Adial Pharmaceuticals Secures U.S.-Based Manufacturing Through Agreements with Cambrex and Thermo Fisher Scientific for Drug Substance and Drug Product Supply

June 25
Last Trade: 0.39 -0.0055 -1.39

Scope of Agreement with Cambrex to Provide Ondansetron HCL Drug Substance Under FDA Approved Drug Master File Scope Of Agreement With Thermo Fisher to Provide Manufacturing Services Including Demonstration, Clinical, Registration And Validation Batches of AD04 for US Clinical Trials And NDA Submission GLEN ALLEN, Va., June 25, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a...Read more


Hoth Therapeutics and Silo Pharma today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty live

June 25
Last Trade: 1.28 -0.01 -0.78

*Hoth Therapeutics and Silo Pharma Launch Joint Venture to Commercialize VA-Invented Obesity Drug Targeting $100B+ Global Market Exclusive License from U.S. Department of Veterans Affairs to Advance GDNF-Based Therapy for Obesity and Fatty Liver Disease NEW YORK, June 25, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH) and Silo Pharma, Inc. (NASDAQ: SILO) today announced the formation of a strategic joint venture to...Read more


Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

June 25
Last Trade: 118.37 -0.65 -0.55

FOSTER CITY, Calif. & WATERTOWN, Mass. / Jun 25, 2025 / Business Wire / Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered into an exclusive option and license agreement to accelerate the development and commercialization of a novel molecular glue degrader (MGD) program targeting cyclin-dependent kinase 2 (CDK2) with broad oncology treatment potential including in...Read more


Evotec Joins NURTuRE-AKI Consortium to Gain Multi-Omics-Based Molecular Understanding of Acute Kidney Injury

June 25
Last Trade: 3.76 -0.06 -1.57

NURTuRE-AKI is a novel observational study that collects longitudinal data and biological samples from fully consented acute kidney injury ("AKI") patients, developed as part of a research consortium led by Kidney Research UK The study focuses on 3 clearly defined cohorts: AKI of iatrogenic origin (following cardiac surgery), AKI to chronic kidney disease ("CKD") transition and pediatric AKI. This partnership will enable...Read more


TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease

June 24
Last Trade: 1.20 0.00 0.00

Study evaluates novel small molecule TNF-alpha inhibitor as potential alternative to biologic treatments NEW YORK / Jun 24, 2025 / Business Wire / TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that it has formed a philanthropic collaboration with the DADA2 Foundation, a...Read more


Ainos and Kenmec Launch Strategic Partnership to Deploy AI-Powered Scent Intelligence in Smart Factories Across Asia

June 24
Last Trade: 3.46 -0.36 -9.42

AI Nose and SLM SmellTech platform enter scale-up phase targeting robotics, automation, and environmental sensing markets Kenmec and Ainos to show case AI Nose and SLM in Automation Taipei 2025 in August SAN DIEGO, CA / ACCESS Newswire / June 24, 2025 / Ainos, Inc. (NASDAQ:AIMD) (NASDAQ:AIMDW) ("Ainos" or the "Company"), a leader in AI-driven scent digitization, today announced it has formed a legally binding strategic partnership...Read more


Lexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA Therapeutics

June 24
Last Trade: 4.72 -0.07 -1.46

Up to $40 Million Private Equity Financing into a New Entity Addressing Cardiac Genetic Diseases that Existing AAV Platforms are Unable to Treat Lexeo Contributing Expertise and Know-How in Cardiac Genetic Medicines, Preclinical Intellectual Property, and Technology, in Combination with Novel Non-Viral RNA Delivery Platform Represents Pipeline Diversification and Advancement of Leading-Edge Cardiovascular Science NEW YORK, June 24,...Read more


Bio-Techne and USP Announce Collaboration to Accelerate Monoclonal Antibody and Gene Therapy Product Development

June 24
Last Trade: 53.60 -0.14 -0.26

MINNEAPOLIS, June 24, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced a distribution agreement with the U.S. Pharmacopeia (USP) that enables the Company to sell USP monoclonal antibody (mAb) and recombinant adeno-associated virus (AAV) reference standards with its analytical solutions, including the Maurice system, to support monoclonal antibody and gene therapy development around the world. More than 160...Read more


Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin

June 24
Last Trade: 8.04 0.14 1.77

Collaboration enables testing of nitrosamine impurities, allowing sponsors to demonstrate acceptable use of rifampin in drug-drug interaction studies DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced a strategic collaboration with Emery Pharma, a leading analytical and bioanalytical CRO providing testing services under current...Read more


GeneDx: Galatea Bio and Fabric Genomics Partner to Deliver Comprehensive Genetic Testing for Common Diseases

June 23
Last Trade: 126.36 3.48 2.83

MIAMI & OAKLAND, Calif. / Jun 23, 2025 / Business Wire / Galatea Bio and Fabric Genomics, a GeneDx company, announced today a strategic collaboration to enhance genetic testing by incorporating both rare pathogenic variant analysis and polygenic risk scoring (PRS) to assess genetic susceptibility to common diseases. The initial offering will include an inherited cardiovascular gene panel based on American Heart Association (AHA)...Read more


Voyageur Pharmaceuticals and Altillion Forge Landmark Alliance to Establish North America's First Vertically Integrated Iodine Drug Supply Chain

June 23
Last Trade: 0.18 0.005 2.94

Calgary, Alberta – TheNewswire - June 23, 2025 – Voyageur Pharmaceuticals Ltd. (TSXV:VM) (“Voyageur” or the “Company”), a Canadian public company developing cost-effective imaging contrast media, is pleased to announce the signing of a non-binding Memorandum of Understanding (MOU) with U.S. based Altillion Inc., a leading technology innovator in mineral extraction. The collaboration marks the launch of Phase 1 in Voyageur’s plan to develop...Read more


Vertex Pharmaceuticals and Ono Pharmaceutical Announce Strategic Agreement to Develop and Commercialize Povetacicept in Japan and South Korea

June 23
Last Trade: 392.79 2.49 0.64

Exclusive collaboration and license agreement for povetacicept in these countries  Ono will leverage its deep expertise in clinical development and commercialization for chronic kidney disease in Japan and South Korea to accelerate advancement of povetacicept for patients with IgA nephropathy and primary membranous nephropathy  BOSTON & OSAKA, Japan / Jun 23, 2025 / Business Wire / Vertex Pharmaceuticals Incorporated...Read more


ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO’s Immune-Enhancing Compounds in Poultry

June 20
Last Trade: 18.25 0.03 0.16

TROY, Mich. / Jun 20, 2025 / Business Wire / ZIVO Bioscience, Inc. (OTCQB: ZIVO), a biotech and agtech R&D company engaged in the development of therapeutic and nutritional products derived from proprietary algal cultures, announces it has entered into a relationship with one of the world’s leading animal health companies to advance ZIVO’s novel immune-boosting compounds for use in multiple poultry market segments. The collaboration is...Read more


Pioneering precision: GE HealthCare aims to elevate clinical care through total body PET/CT technology with Stanford Medicine

June 19
Last Trade: 73.40 -0.26 -0.35

GE HealthCare and the Department of Radiology at Stanford Medicine aim to explore total body positron emission tomography/computed tomography (PET/CT) technology for new clinical pathways to help improve patient outcomes. Total body PET/CT technologyi is designed with the goal of supporting personalized medicine practices like theranostics, improve healthcare system efficiency, and provide scalable solutions for imaging practices and...Read more


Beta Bionics Announces Agreement with Abbott to Integrate the iLet Bionic Pancreas with Abbott’s Future Dual Glucose-Ketone Sensor

June 19
Last Trade: 0 0.00 0.00

IRVINE, Calif., June 19, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc., a pioneering leader in the development of advanced diabetes management solutions, announced its intention to integrate its iLet Bionic Pancreas automated insulin delivery (AID) system with Abbott's future dual glucose-ketone sensor in the U.S. The iLet represents a significant advancement in diabetes care as the first and only AID system that makes 100% of insulin...Read more


QIAGEN and GENCURIX Announce QIAcuity Digital PCR IVD Assay Development Partnership

June 18
Last Trade: 49.35 0.39 0.80

GENCURIX partnership marks launch of new QIAcuityDx Partnering Program for third-party in vitro diagnostic (IVD) assay development GENCURIX signs as inaugural partner to develop multiplex oncology assays for tissue and liquid biopsies Partnership aims to broaden adoption of QIAcuityDx Four platform offering clinical diagnostic laboratories a range of clinical oncology assays VENLO, Netherlands / Jun 18, 2025 / Business Wire / QIAGEN...Read more


BioAge Labs Expands Drug Discovery Platform with Data from Leading European Biobank

June 17
Last Trade: 4.55 0.09 2.02

Company to generate and analyze molecular profiles from over 17,000 samples from the HUNT Biobank in Norway to accelerate discovery of drug targets for aging-related diseases New data deepen platform insights into the biology of resilience across multiple therapeutic indications EMERYVILLE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biotechnology company...Read more


Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and Development

June 17
Last Trade: 2.53 -0.03 -1.17

Expanded alliance combines Lisata’s drug development expertise with GATC’s AI-powered Multiomics Advanced Technology® platform to accelerate and improve success rates of next-generation drug development Lisata to lead development efforts to advance GATC’s AI-discovered therapeutic for opioid use disorder into human clinical trials early in 2026 BASKING RIDGE, N.J. and IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) -- Lisata...Read more


Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

June 17
Last Trade: 1.23 -0.007 -0.56

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), for current good...Read more


Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

June 17
Last Trade: 4.63 0.08 1.76

Partnership aims to accelerate precision immunotherapy by leveraging AI-powered virtual cell models to identify which patients are most likely to benefit from BOT/BAL treatment Collaboration builds on landmark 2024 Cancer Discovery study elucidating botensilimab’s unique FcγR-mediated immune activation underlying activity in refractory tumors. Supports AI-enabled biomarker discovery, aligning with the national priorities and the FDA to...Read more


Castle Biosciences Enters Collaboration and License Agreement with SciBase to Develop Diagnostic Tests for Dermatologic Diseases

June 16
Last Trade: 20.09 0.27 1.36

Initial Development Project Targets Predicting Flares in Patients Diagnosed with Atopic Dermatitis FRIENDSWOOD, Texas, June 16, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has entered into a collaboration and license agreement with SciBase Holding AB (“SciBase”) utilizing SciBase’s Electrical Impedance...Read more


Teva Pharmaceutical and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

June 16
Last Trade: 17.86 0.32 1.82

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Growth strategy TEL AVIV, Israel and...Read more


Charles River Laboratories Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

June 16
Last Trade: 156.68 0.88 0.56

A solution for laboratories seeking to reduce single-use plastic waste WILMINGTON, Mass. / Jun 16, 2025 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced a recycling program, developed in partnership with international recycling leader TerraCycle®, to give new life to single-use plastic cartridges. This groundbreaking collaboration offers users of Charles River’s Endosafe® bacterial endotoxin...Read more


NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

June 16
Last Trade: 5.12 -0.04 -0.68

NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rights Phase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third quarter of 2025 Initial Phase 1 clinical data is expected in the first half of 2026 NextCure also gains rights to Simcere Zaiming’s proprietary linker and payload for use in an ADC directed to a NextCure novel...Read more


QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

June 15
Last Trade: 49.35 0.39 0.80

QIAGEN to create a multimodal panel using next-generation sequencing (NGS) technology for detecting clinically relevant gene alterations in hematological malignancies Companion diagnostic to identify key disease-causing mutations in patients with MPNs, with an initial focus on mutant CALR the second most common driver of MPNs Panel to be validated on Illumina NextSeq 550Dx platform for use with whole blood samples Partnership supports...Read more


Tempus AI Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research

June 12
Last Trade: 73.68 2.09 2.92

CHICAGO / Jun 12, 2025 / Business Wire / Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a collaboration with The Abrams Research Center on Neurogenomics at Northwestern University Feinberg School of Medicine. This multi-year collaboration aims to harness AI for rapid discovery and innovation in Alzheimer's disease research. The collaboration...Read more


BullFrog AI Announces Strategic Collaboration with Sygnature Discovery to Introduce BullFrog Data Networks™ to Global Biopharma Clients

June 12
Last Trade: 1.25 -0.03 -2.34

GAITHERSBURG, Md., June 12, 2025 (GLOBE NEWSWIRE) -- BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) ("BullFrog AI" or the "Company"), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, today announced a strategic collaboration with Sygnature Discovery, a leading UK-based contract research organization (CRO)...Read more


MaxCyte and Ori Biotech Collaborate to Improve Manufacturing Efficiencies and Broaden Adoption of Autologous Cellular Therapies

June 11
Last Trade: 1.36 -0.05 -3.55

MaxCyte and Ori Biotech successfully integrate their ExPERT™ and IRO® platforms to improve the yield of gene-edited T cells and shorten manufacturing timelines ROCKVILLE, Md. and LONDON, June 11, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell...Read more


Bexorg Announces Research Collaboration with Biohaven Leveraging Its Novel AI-Driven Whole-Brain Discovery Platform to Enhance CNS Drug Development

June 10
Last Trade: 15.71 1.48 10.40

NEW HAVEN, Conn., June 10, 2025 (GLOBE NEWSWIRE) -- Bexorg, Inc., a pioneering techbio company working to decode the human brain and advance new therapies for central nervous system (CNS) disorders, today announced a multi-program research collaboration with Biohaven Ltd. (NYSE: BHVN) to identify, de-risk, and advance next-generation therapies for CNS disorders. As part of the collaboration, Bexorg’s novel whole-brain discovery platform...Read more


WELL Health Technologies: CRH Medical and WovenX Announce Strategic Partnership to Advance GI Patient Access and Streamline Care Delivery

June 10
Last Trade: 4.78 0.08 1.70

Collaboration merges clinical and operational expertise with virtual-first innovation to eliminate barriers to GI care. ATLANTA & CHICAGO / Jun 10, 2025 / Business Wire / CRH Medical Corporation (“CRH”), a leading provider of products and services for gastrointestinal (GI) providers and a wholly owned subsidiary of WELL Health Technologies Corp. (“WELL”), has announced a strategic partnership with WovenX Health (“WovenX”), a leader...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE